CLEC-2 prevents the activation of Ser and Thr kinase (AKT) and glycogen synthase kinase 3β (GSK3β) signaling in a spleen tyrosine kinase (SYK)-dependent manner, as well as the invasiveness and expression of EMT markers in cancer cell lines, which suppressed gastric cancer cell metastasis [151]. Here, SYK is linked to cancer.